

Please type a plus sign (+) inside this box → ☐Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

5

of

6

**Complete if Known**

Application Number	09/585,821
Filing Date	June 1, 2000
First Named Inventor	Wilkison <i>et al.</i>
Group Art Unit	1645
Examiner Name	
Attorney Docket Number	08140.105004

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
/J.R./	A	4,526,988		Larry W. Hertel	07-02-1985	
/J.R./	B	5,336,764		Marquez <i>et al.</i>	08-09-1994	
/J.R./	C	5,446,045		Revankar <i>et al.</i>	08-29-1995	
/J.R./	D	5,684,143		Gryaznov <i>et al.</i>	11-04-1997	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T 0 2 - 6
		Office <sup>3</sup>	Number	Kind Code <sup>2</sup> (if known)				
/J.R./	E	EP	0145978		Bristol-Myers Company	06-26-1985		
/J.R./	F	WO	96/29336		Medical Research Council <i>et al.</i>	09-26-1996		

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 6
/J.R./	G	BENSELER, Fritz <i>et al.</i> ; "Synthesis of Suitable-Protected Phosphoramidites of 2'-Fluoro-2'-Deoxyguanosine and 2'-Amino-2'-Deoxyguanosine for Incorporation into Oligoribonucleotides;" <i>Nucleosides &amp; Nucleotides</i> , 11(7), 1333-1351 (1992)	
/J.R./	H	CODINGTON, John F. <i>et al.</i> ; "Nucleosides: Synthesis of 2-Deoxy-2-Fluoro-D-Ribose," <i>Carbohydrate Research</i> , 1, (1966), 455-466	
/J.R./	I	CODINGTON, John F. <i>et al.</i> ; Nucleosides XIV: Synthesis of 2-Deoxy-2-Fluorouridine," <i>Communications to the Editor; J. Amer Chem. Soc.</i> , Vol. 83; pp. 5030-5031, (1961).	
/J.R./	J	CODINGTON, John F. <i>et al.</i> ; ; Nucleosides XVIII: Synthesis of 2' Fluorothymidine, 2' Fluorodeoxyuridine, and Other 2' Halogeno-2'-Deoxy Nucleosides; <i>J. Amer Chem. Soc.</i> , Vol. 29; pp.558-564, March 1964	
/J.R./	K	FORD, Harry <i>et al.</i> ; "Chemistry and Anti-HIV Activity of 2'-β-Fluoro-2',3'-Dideoxyguanosine"; <i>Nucleosides &amp; Nucleotides</i> ; 13(1-3), pp. 213-234 (1994)	

Examiner  
Signature

/Jezia Riley/

Date

Considered

02/13/2011

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.R./